ATE251448T1 - Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen - Google Patents

Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen

Info

Publication number
ATE251448T1
ATE251448T1 AT99968164T AT99968164T ATE251448T1 AT E251448 T1 ATE251448 T1 AT E251448T1 AT 99968164 T AT99968164 T AT 99968164T AT 99968164 T AT99968164 T AT 99968164T AT E251448 T1 ATE251448 T1 AT E251448T1
Authority
AT
Austria
Prior art keywords
oil suspensions
polyol
proteins
delayed release
active agent
Prior art date
Application number
AT99968164T
Other languages
English (en)
Inventor
Merrill Seymour Goldenberg
Daxian Shan
Alice C Beekman
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/221,181 external-priority patent/US6245740B1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE251448T1 publication Critical patent/ATE251448T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
AT99968164T 1998-12-23 1999-12-20 Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen ATE251448T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/221,181 US6245740B1 (en) 1998-12-23 1998-12-23 Polyol:oil suspensions for the sustained release of proteins
US44820599A 1999-11-23 1999-11-23
PCT/US1999/030527 WO2000038652A1 (en) 1998-12-23 1999-12-20 Polyol/oil suspensions for the sustained release of proteins

Publications (1)

Publication Number Publication Date
ATE251448T1 true ATE251448T1 (de) 2003-10-15

Family

ID=26915566

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968164T ATE251448T1 (de) 1998-12-23 1999-12-20 Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen

Country Status (16)

Country Link
EP (1) EP1140018B1 (de)
JP (1) JP2002533378A (de)
KR (1) KR100491815B1 (de)
CN (1) CN1158068C (de)
AT (1) ATE251448T1 (de)
AU (1) AU769610B2 (de)
CA (1) CA2355618C (de)
DE (1) DE69911993T2 (de)
DK (1) DK1140018T3 (de)
ES (1) ES2204187T3 (de)
HU (1) HUP0104756A3 (de)
IL (2) IL143706A0 (de)
PT (1) PT1140018E (de)
SI (1) SI1140018T1 (de)
TW (1) TWI221777B (de)
WO (1) WO2000038652A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
JP4361710B2 (ja) 2000-04-19 2009-11-11 ジェネンテック・インコーポレーテッド 徐放製剤
US20020197235A1 (en) * 2000-11-03 2002-12-26 Moran Stanford Mark Method for short-term and long-term drug dosimetry
EP1397155B1 (de) * 2001-06-21 2015-09-30 Genentech, Inc. Formulierung mit verzögerter freisetzung
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
US7803769B2 (en) 2006-10-25 2010-09-28 Amgen Inc. OSK1 peptide analogs and pharmaceutical compositions
CN101610754A (zh) 2007-02-16 2009-12-23 Aska制药株式会社 含有微粒油性混悬液的药物组合物
WO2008106571A2 (en) 2007-02-28 2008-09-04 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US8420779B2 (en) 2007-05-22 2013-04-16 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
MX352878B (es) 2009-09-28 2017-12-13 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
BR112013023674A2 (pt) 2011-03-16 2016-12-13 Amgen Inc inibidores potentes e seletivos de nav1.3 e nav1.7
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
UY35397A (es) 2013-03-12 2014-10-31 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
MX370689B (es) 2014-06-10 2019-12-19 Amgen Inc Polipeptidos apelina.
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP4278996A3 (de) 2015-06-03 2024-01-24 i2o Therapeutics, Inc. Systeme zum einsetzen eines implantats
EP3458084B1 (de) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3482657D1 (de) * 1983-11-21 1990-08-09 Univ Minnesota Gepuffertes polyol-hormones gemisch zur verwendung bei chronischer parenteraler hormonverabreichung.
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
EP0374120A3 (de) * 1988-12-13 1991-07-31 Monsanto Company Zusammensetzung mit kontrollierter Wirkstoffabgabe von Polypeptiden
US5114929A (en) * 1989-03-21 1992-05-19 Beecham Group P.L.C. Pharmaceutical formulation
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions

Also Published As

Publication number Publication date
CA2355618A1 (en) 2000-07-06
IL143706A (en) 2008-04-13
HUP0104756A3 (en) 2006-04-28
JP2002533378A (ja) 2002-10-08
CN1335765A (zh) 2002-02-13
ES2204187T3 (es) 2004-04-16
SI1140018T1 (en) 2003-12-31
WO2000038652A1 (en) 2000-07-06
AU769610B2 (en) 2004-01-29
CN1158068C (zh) 2004-07-21
AU2483800A (en) 2000-07-31
DE69911993D1 (de) 2003-11-13
EP1140018B1 (de) 2003-10-08
CA2355618C (en) 2007-03-13
IL143706A0 (en) 2002-04-21
KR20010099864A (ko) 2001-11-09
EP1140018A1 (de) 2001-10-10
KR100491815B1 (ko) 2005-05-27
DK1140018T3 (da) 2004-02-02
PT1140018E (pt) 2004-02-27
DE69911993T2 (de) 2004-05-19
TWI221777B (en) 2004-10-11
HUP0104756A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
ATE251448T1 (de) Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
ATE309007T1 (de) Transplantate für die wiederherstellung von osteochondralen schäden
CO5271726A1 (es) Composicion farmaceutica soluble en agua en un complejo ionico y el uso de la misma
BR9810495A (pt) Composição farmacêutica
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
AU7931301A (en) Method of using diketopiperazines and composition containing them
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
DE69819145D1 (de) Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung
BR9811094A (pt) Agente terapêutico para tumores linfáticos
IT1299583B1 (it) Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
ES2160410T3 (es) Preparados de complejos de protrombina inmunotolerantes.
EA200400041A1 (ru) Сочетание действующих ингредиентов, используемое в качестве вызывающего привыкание фармакологического средства или для интоксикационной терапии
EA199900642A1 (ru) Твердые смеси на базе сульфонилкарбамидов и вспомогательных агентов
EP0995430A3 (de) Verwendung von Wirkstoffen, gewählt aus der Gruppe der 1,2-Diacylglycerole, zur Stärkung der Barrierefunktion der Haut
RS49955B (sr) Stabilne kompozicije koje sadrže levosimendan i alginsku kiselinu
WO2001037780A8 (en) Urotensin-ii analogs
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
ATE299704T1 (de) Warmgeformte feste arzneizusammensetzung zur gesteuerten wirkstoffabgabe von perindopril
ATE179075T1 (de) Stabilisierte pharmazeutische zusammensetzungen enthaltend dobutamine
TR199902605T2 (xx) Fibrinojenin azalt�lma y�ntemleri.
DE50002875D1 (de) Hepatitis a viruzid
BR0001650A (pt) Composições para o controle de baratas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140018

Country of ref document: EP

REN Ceased due to non-payment of the annual fee